Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)

Abstract

Background: Patients' experiences regarding topical actinic keratosis (AK) treatments may optimize clinical outcomes. PROAK study aimed to evaluate patient- and clinician-reported outcomes among adult patients with AK on face or scalp who were prescribed tirbanibulin in real-world clinical practice in the United States.
 Methods: Key primary endpoint was quality of life (QoL) assessed by Skindex-16. Additional endpoints were tirbanibulin treatment effectiveness and satisfaction (Treatment Satisfaction Questionnaire for Medication and Expert Panel Questionnaire).
 Results: 290 patients were included in this analysis. At week 8, Skindex-16 scores improved in all domains (mean change from baseline [standard deviation, SD]: -14.3 [27.8] in symptoms, -24.9 [33.0] in emotions, and -9.8 [23.7] in functioning domain). Clinicians and patients reported high global satisfaction with tirbanibulin (mean [SD] scores of 78.8 [20.1] and of 74.5 [23.5]). Overall skin appearance improved from baseline to week 8 (91.0% clinicians; 84.1% patients). In comparison with previous treatments, tirbanibulin had shorter skin reactions duration (89.2% clinicians; 73.9% patients); milder skin reaction severity (91.0% clinicians; 76.6% patients); better daily activities impact (87.4% clinicians; 64.0% patients); and was easier to use (88.3% clinicians; 71.2% patients). Investigator’s Global Assessment (IGA) success (0-1) was achieved by 73.8% of the patients. Skin photodamage severity reduction from baseline to week 8 was significant (77.4% vs. 39.6%; p<0.0001).
 Conclusions: Tirbanibulin treatment demonstrated effectiveness in AK management. Moreover, tirbanibulin improved QoL, as early as week 8, and both clinicians and patients reported tirbanibulin treatment convenience, and high levels of treatment satisfaction, compared to patient’s previous treatments.

The Role of Field Cancerization in Selecting Therapies for Actinic Keratosis: An Expert Consensus Panel

“…In another study of clinician-and patient-reported outcomes, 73.9% of patients and 89.2% of clinicians felt that tirbanibulin had a shorter duration of skin reactions than previous field treatments. 28 Additionally, 91% of clinicians and 76.6% of patients reported that tirbanibulin had milder skin reaction severity than prior field treatments. 28 The tolerability of tirbanibulin makes it more likely that patients will be compliant with therapy and effectively eradicate their AKs.…”

“…28 Additionally, 91% of clinicians and 76.6% of patients reported that tirbanibulin had milder skin reaction severity than prior field treatments. 28 The tolerability of tirbanibulin makes it more likely that patients will be compliant with therapy and effectively eradicate their AKs. 1485 can be very effective, only field-directed therapy is able to treat subclinical lesions and reduce FC.…”

“…Of the 21 articles that were reviewed, the panel assigned level 1 evidence to three articles [21][22][23] , level 2 evidence to six articles [24][25][26][27][28][29] , and level 3 evidence to twelve articles 12,[30][31][32][33][34][35][36][37][38][39][40] (Table 1).…”